USCOM LIMITED — Regulatory Filings 2021

Aug 10, 2021

ASX MEDIA RELEASE

Five New Software Copyrights for BP+ in China

• Wide IP Protection of BP+ Core Performance in China

• • Three additional BP+ Software Patents in Progress - Total China IP Submissions Now 42

SYDNEY, Australia, Wednesday 11[th] August 2021: Uscom Limited (ASX code: UCM) (the Company or Uscom ) today notified the market that Uscom China has recently received five new software copyrights covering the core performance and function of the Uscom BP+ central BP monitor. These approvals consolidate Uscom’s IP strategy in China taking the current accepted and submitted patents, copyrights and trademarks in China to 42.

Background:

Hypertension is the leading modifiable risk factor for cardiovascular disease and death and occurs in approximately 1/3 of all Chinese adults and is associated with a with a 4 times incidence of cardiovascular disease and mortality. In China less than 50% of hypertensive patients are treated, and of these less than 30% have effective BP control, with an overall control rate of 4.2%. The new BP+ suprasystolic oscillometric technology allows for more precise monitoring of the blood pressure in the arms and in the heart, resulting in improved therapy and outcomes, and is an important advancement for both Uscom and hypertensive and vascular care in China. The NMPA approved the sale of BP+ in April 2021.

Operations:

Uscom China is Uscom’s largest global subsidiary according to sales revenue, and this has grown solely on the sale of the USCOM 1A device for management of Sepsis, fluid management, heart failure and hypertension in pregnancy or preeclampsia. With the NMPA approval of BP+, Uscom China now has an additional source of revenue, and to ensure our technology is IP protected multiple patents, copyrights and trademarks have been initiated. These five recent approvals provide IP protection for the core BP+ functions, while three others are still under review.

China has strategically identified IP as an area of desired expansion and high value, with Uscom China stamped as a National High Tech Medical Enterprise by the High Torch Subsidiary of the Ministry of Science and Technology for significant achievements in research and development (R&D), innovations, Intellectual property (IP) generation, and transformational outcomes in high technology fields.

Commentary:

Executive Chairman of Uscom, Professor Rob Phillips said “China is realising the value of IP in the global technology market place and encouraging the development of IP as a means to protect market interest. Increasingly Chinese IP laws are aligned with international laws and accessible to foreign companies as a means of protecting IP theft. Companies in China are increasingly being actively encouraged to lodge patents, trademarks and copyrights, and Uscom, with its high technology devices, is developing a significant portfolio of Chinese registered IP. These recent awards of BP+ IP will provide us with commercial protection as we develop the substantial Chinese hypertension market with our newly NMPA approved BP+.”

References: Lewington S, Lacey B, Clarfke R, et al. The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China. JAMA Intern Med 2016; 176(4):524-32. DOI:10.1001/JAMAINTERNMED.2016.0190.

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, SpiroReporter , with wireless interfacing to provide remote telemonitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au

Uscom Contacts Rob Phillips Chairman rob@uscom.com.au

Brett Crowley Company Secretary

This announcement is approved for release to the ASX by the Board of Uscom Limited.

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au